Dr. Lal PathLabs Limited announced the launch of SOVAAKA, its new-age Diagnostic Experience Centre in Gurugram on January 6, 2026. The initiative represents a significant advancement in preventive healthcare, combining precision diagnostics with cutting-edge technology to deliver personalized wellness solutions.

Advanced Wellness Philosophy

Built on the philosophy of "Science Behind Wellness," SOVAAKA introduces a new standard in preventive and lifestyle healthcare. The centre brings together precision diagnostics, cutting-edge technology, and medical expertise to help individuals take proactive control of their health. This advanced wellness initiative goes beyond routine health checks to offer a deeply personalized diagnostics-led wellness experience.

Personalized Programs and Services

SOVAAKA offers doctor-designed programs customized to individual needs:

The centre integrates advanced diagnostics including high-sensitivity blood panels, genetic testing, AI-supported imaging, and seamlessly integrated digital health records. With end-to-end clinical report evaluation and tailored nutrition guidance, SOVAAKA delivers comprehensive understanding of health and wellness trajectory.

Technology and Equipment

The facility is equipped with state-of-the-art medical technology to ensure comprehensive health assessment:

The centre ensures fast turnaround times, comprehensive insights, and deeply personalized evaluation experiences for all patients.

Leadership Perspectives

(Hony) Brig. Dr. Arvind Lal, Executive Chairman of Dr. Lal PathLabs, emphasized the transformative nature of the initiative: "SOVAAKA marks a pivotal moment in the evolution of diagnostics — from disease detection to disease prediction. In a world where Non-Communicable Diseases (NCDs) or Lifestyle Diseases are affecting millions silently, science-led wellness and early screening play a transformative role."

Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs, highlighted the comprehensive approach: "With SOVAAKA, we are reimagining how preventive healthcare is delivered. By bringing diagnostics, advanced imaging, and lifestyle-based programmes under one roof, we are creating a destination for individuals committed to investing in their long-term health."

Market Context and Strategic Positioning

The launch comes at a time when India is witnessing rapid growth in the preventive health and wellness segment. This growth is driven by increasing incidence of Non-Communicable Diseases, rising awareness, evolving lifestyles, and greater emphasis on early detection. With SOVAAKA, Dr. Lal PathLabs strengthens preventive care by offering comprehensive, evidence-backed solutions that empower individuals to understand their health better and act early.

SOVAAKA represents the premium wellness vertical from Dr. Lal PathLabs, merging diagnostic excellence, medical expertise, and AI technology to offer personalized, preventive, and predictive health experiences. The centre positions the company at the forefront of the evolving healthcare landscape, focusing on proactive health management rather than reactive treatment approaches.

Dr. Lal PathLabs Limited has announced that its Board of Directors will meet on January 30, 2026, to consider and approve the company's unaudited financial results for the third quarter of fiscal year 2026. The meeting will address both standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. Additionally, the company will host an earnings conference call on the same day to discuss the financial and operating performance with investors and analysts.

Board Meeting Details

The healthcare company has scheduled the board meeting in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will specifically focus on reviewing and approving the unaudited financial performance for the specified period.

Earnings Conference Call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Dr. Lal PathLabs will host an earnings conference call for investors and analysts on Friday, January 30, 2026, at 4:00 PM IST. The call will discuss the financial and operating performance for Q3 & 9M FY26.

The conference call will begin with a brief discussion by management on Q3 & 9M FY26 financial and operating performance, followed by a question-and-answer session for participants.

Trading Window Closure

In compliance with regulatory requirements, Dr. Lal PathLabs has announced the closure of its trading window for company securities. This measure aligns with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code for Prevention of Insider Trading.

Company Overview

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brands in diagnostic services with an integrated nationwide network. The company offers a broad range of diagnostic and related healthcare tests and services, with a catalogue including 385 test panels, 3,172 pathology tests and 1,455 radiology and cardiology tests. The company operates 298 clinical labs, 6,607 Patient Service Centers and 12,365 Pick-up Points, processing approximately 86 million samples from 28.8 million patients.